Occulogix (MM) (OCCX) News

Just thought I'd post this:

OccuLogix Provides Progress Update on the Commercial Development of Its TearLab(TM) Osmolarity System

9:03a ET October 15, 2008 (Market Wire)

OccuLogix, Inc. (NASDAQ: OCCXD)(TSX: OC) provided an update today on the progress made by its wholly-owned subsidiary, OcuSense, Inc., in the commercial development of its TearLab(TM) Osmolarity System ("TearLab(TM)").

TearLab(TM) has recently received CE mark approval, clearing the way for sales in the European Union and all countries recognizing the CE Mark. In connection with the CE mark clearance, OcuSense has achieved multi-year agreements with four distributors for exclusive distribution of TearLab(TM) in five European Union countries. Beginning immediately, TearLab(TM) will be available in:

- United Kingdom and the Republic of Ireland distributed by the Birmingham Optical Group;

- Germany distributed by Bon Optic;

- Spain distributed by Equipsa; and

- Italy distributed by SIFI Diagnostics

Additional European countries will be added during the coming months as the Company expands its distribution network.

"The introduction of TearLab(TM) into the eye care market addresses the unmet need for simple, point-of-care tests that can generate objective physiological data for improving the quality of clinical decision making," said Eric Donsky, OccuLogix' CEO.

"In addition, the ability to perform tear osmolarity testing in the office, using any member of the clinical staff, is a significant improvement upon current methods of assessing tear osmolarity," continued Donsky.

About Osmolarity

Studies have shown that osmolarity, the measurement of total solute concentration in patients' tears, is objective and quantitative, and a highly specific biomarker.(i) In dry eye disease, the accuracy of tear film osmolarity is considered superior to any other single test for dry eye analysis, including Lactoplate, Schirmer's test, and corneal staining.(ii)

Measuring osmolarity using current in-lab testing technologies presents a challenge because of the need for large volumes of tear fluid. Currently, osmolarity can only be tested in reference labs, which makes this type of testing difficult because of the need to either ship samples and risk evaporation, or require the patient to travel to a lab for testing.

About TearLab(TM)

The introduction of the TearLab(TM) Osmolarity System marks a significant change in how tear osmolarity testing will be conducted. The TearLab(TM) technology uses a novel "lab-on-a-chip" approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear osmolarity. By using such a small amount of tears, the TearLab(TM) Osmolarity System mitigates issues that have hindered practical, objective point-of-care osmolarity testing. The system consists of three components: the TearLab(TM) Osmolarity Test Card, the TearLab(TM) Reader and the TearLab(TM) Pen.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. Its wholly-owned subsidiary, OcuSense, Inc. (www.ocusense.com) is an in vitro diagnostics company developing and commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

Looks like your instinct was right...the stock shot up on recent news after the recent reverse stock split.

I have some info on the company that is encouraging...

First off this is a legit company. I know someone who works for the company (they are married to a colleague of mine) and have heard from that person that the launch in Europe went well. The launch here in the US was postponed because they are still working on getting approvals for the Occusense Equipment, but the launch will take place and it will be national. Also, they put out a call for private investment and were able to raise enough money that they didn't have to look at venture capital firms for money. In fact, a great deal of medical doctors were clamoring to get in on the ground level with investments. That says to me that the product is solid. Right now they will limit the equipment's analysis capabilities to diseases of the eye, but the potential is unlimited since there are a vast number of genetic tests that one could envision using the Occusense system for that don't even have anything to do with vision. Any how, that is my 2 cents. I have invested $5,000 in the company and my friend and spouse invested the minimum $25,000 when they joined the company (and got the preferred value stock). I think the reverse stock split was a good move because they need to stay legal with the NASDAQ people.

This is my first post here, but I will stick around as this company continues to grow and progress. They have very good business and scientific leadership at the top and I feel good about them.

OCCX looks like it could move higher especially if it consolidates a little more around this level. good volume. definitely one to watch.

weeeee... having fun yet?

sure nuf, lol
Best to you sklein870.
-V. =)

Thanks... Doing great!

You take care as well. Hoping to see some interest in NWTT before the end of the month.

And to think I did DD on this last month and let it go.
Lol. wow.
Congrats on the recents 1000% run. =)

OCCX going to .44-.45 and or .50 would be a sell. IMO

Posted by: Threeflight
In reply to: mark3554 who wrote msg# 1560
Date:1/30/2008 12:07:13 AM
Post #of 1599

OCCX-Nasdaq shell-at .06/$6 M cash/0 debt looking for merger/book value of 83 cents

This used to be RHEO, an eye company on the Nasdaq that traded for $10-$12. I used to trade it all the time in the dollars. Recently they disbanded their hopes of their RHEO™ System for the treatment of dry age-related macular degeneration ever being a huge market seller. This was the company's main target as far as making money. Now the stock has fallen all the way to 6 cents!

They are now essentially a shell looking for a merger or some other avenue of making money. The thing is, they have NO debt and $6 Million in cash. Book value is around 83 cents if you add in their other assets. Their cash value for JUST the money they have in the bank is over ten cents. They file complete financials. They are on the NASDAQ. They are looking at a new acquisition, a new merger per a recent PR, whatever. It doesn't matter. As soon as they announce any type of move, with only a 57 M OS and a 28 M float, this is going back to a dollar.

Here is a recent PR....

"The remaining members of OccuLogix' executive team will continue to concentrate their efforts on raising additional financing for the Company, on assessing strategic alternatives to maximize shareholder value, and on managing OccuLogix' ownership stake in OcuSense, Inc. In support of those goals, Elias Vamvakas (Chairman and Chief Executive Officer) and Tom Reeves (President and Chief Operating Officer) have both agreed to accept a 50% reduction of their salaries commencing on February 1, 2008.

As first announced on October 9, 2007, OccuLogix continues to explore the full range of strategic alternatives available to it to maximize shareholder value. These alternatives may include, but are not limited to, the raising of capital through the sale of securities, one or more strategic alliances and the combination, sale or merger of all or part of the Company. OccuLogix stated that there can be no assurance that the exploration of strategic alternatives will result in a transaction. The Company does not intend to disclose developments with respect to the exploration of strategic alternatives unless and until its Board of Directors has approved a specific transaction."

Look at some of these valuation measures...

VALUATION MEASURES
Market Cap (intraday)5: 3.55M (they have cash worth 6 million)
Enterprise Value (29-Jan-08)3: -2.80M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-08) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 11.50
Price/Book (mrq): 0.07
Enterprise Value/Revenue (ttm)3: -9.22
Enterprise Value/EBITDA (ttm)3: 0.114
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-Dec
Most Recent Quarter (mrq): 30-Sep-07
Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): -10087.81%
Management Effectiveness
Return on Assets (ttm): -25.54%
Return on Equity (ttm): -52.67%
Income Statement
Revenue (ttm): 303.85K
Revenue Per Share (ttm): 0.006
Qtrly Revenue Growth (yoy): -82.20%
Gross Profit (ttm): -3.34M
EBITDA (ttm): -24.50M
Net Income Avl to Common (ttm): -29.37M
Diluted EPS (ttm): -0.534
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 6.24M
Total Cash Per Share (mrq): 0.109
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 0.951
Book Value Per Share (mrq): 0.835
Cash Flow Statement
Operating Cash Flow (ttm): -17.00M
Levered Free Cash Flow (ttm): -7.45M
View Financials (provided by EDGAR Online):
Income Statement - Balance Sheet
Cash Flow

Any type of merger they announce, I'm assuming with another eye company, and with the short here and the way this has been beaten down takes to a dollar. This is unlike other shells. There is no debt. They have millions in the bank. They already file financials.

Its a beautiful setup for someone looking to go public.
Look at this chart. It has bottomed and is ready to move u

ready?

Time to move up, giddy up!

OccuLogix, Inc. (NASDAQ:OCCX) today announced that it now expects to release its Q3-07 financial results on or about November 9, 2007.

Financials out tomorrow.. up 15%? Hmm.. does somebody know something?

Is this the turn?

Here's what caused today's tank.

OccuLogix Suspends RHEO(TM) System Clinical Development Program
Thursday November 1, 8:30 am ET

BOSTON, MASSACHUSETTS--(MARKET WIRE)--Nov 1, 2007 -- OccuLogix, Inc. (NasdaqGM:OCCX - News)(Toronto:OC.TO - News) today announced that following a comprehensive review of the respective costs and development time-lines associated with the products in its portfolio, and in light of the Company's current financial position, its Board of Directors and management have indefinitely suspended its RHEO(TM) System clinical development program in Dry Age-Related Macular Degeneration.

OccuLogix management and advisors also continue to explore the full range of strategic alternatives available to enhance shareholder value, as previously disclosed in the Company's press release of October 9, 2007. These alternatives may include, but are not limited to, the raising of capital through the sale of securities, one or more strategic alliances and the combination, sale or merger of all or part of the Company. OccuLogix stated that there can be no assurance that the exploration of strategic alternatives will result in a transaction.

The Company does not intend to disclose developments with respect to the exploration of strategic alternatives unless and until its Board of Directors has approved a specific transaction. Accordingly, while OccuLogix still intends to announce its Q3-07 financial results on Wednesday, November 7, 2007, it has decided to cancel the planned conference call previously scheduled for November 7, 2007 at 8:30 a.m. Eastern Time during which those results were to be discussed.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.


Contact:

Contacts:
OccuLogix, Inc.
Stephen Kilmer
VP, Investor & Public Affairs
(905) 602-0887 ext. 3904
Email: stephen.kilmer@occulogix.com
Website: http://www.occulogix.com

Not a buy right now IMO.. but tanking nicely LOL.

Need news to increase the volume here.

Waiting one more day for confirmation.

Actually... looks to be ready to go. Nice time to open a position IMO.

.35, .40, .50 seems to be resistance points. Good time for news. Good luck and happy trading!

Not at bottom yet.

nice call startingboy ... chart looks good

http://stockcharts.com/h-sc/ui?s=OCCX&p=D&yr=0&mn=3&dy=0&id=p36545807245&a=1...

looks good for a nice bounce from here

Oversold with an Improving RSI (OCCX)

Parabolic SAR Buy Signals (OCCX)

9-Aug-07 Caris & Company Upgrade (Below Average) to (Average)

OccuLogix Reports Q2-07 Financial Results
OccuLogix, Inc.

(NASDAQ: OCCX)(TSX: OC) today reported its consolidated financial results for the three months ended June 30, 2007. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

For the second quarter of 2007, net revenues were $121,275 compared to $82,715 in the second quarter of 2006. The Q2-07 net loss was $2.6 million, or $0.05 per share. This compared to the Q2-06 net loss of $70.0 million, or $1.66 per share, which included a goodwill impairment charge of $65.9 million.

As of June 30, 2007, the Company had cash and cash equivalents and short term investments of $15.6 million.

Conference Call and Webcast Information

OccuLogix will hold a conference call to discuss these results today, August 8, at 8:30 a.m. Eastern Time at 800-926-5187 (within the United States and Canada), or 212-231-2900 (international callers). The call will also be broadcast live and archived on the company's website at www.occulogix.com under the "webcasts" link in the Investor Relations section. For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone 416-626-4100 and enter reservation # 21345225 when prompted.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. OccuLogix is currently focused in the areas of: Dry AMD through its RHEO(TM) System (www.rheo.com); Glaucoma through its SOLX® 790 Laser and SOLX® Gold Shunt (www.solx.com); and Dry Eye Disease through the company's subsidiary, OcuSense, Inc. (www.ocusense.com).

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

OccuLogix, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS
(expressed in U.S. dollars except number of shares)
(Unaudited)

Three months ended
June 30,
-------------------------
2007 2006
$ $
---------------------------------------------------------------------------
---------------------------------------------------------------------------

Revenue
Retina - 82,715
Glaucoma 121,275 -
---------------------------------------------------------------------------
Total revenue 121,275 82,715
---------------------------------------------------------------------------
Cost of goods sold
Retina
Cost of goods sold, net of goods recovered 8,297 (20,683)
Royalty costs 25,000 25,000
Glaucoma
Cost of goods sold 42,464 -
Royalty costs 6,250 -
---------------------------------------------------------------------------
Total cost of goods sold 82,011 4,317
---------------------------------------------------------------------------
39,264 78,398
---------------------------------------------------------------------------
Operating expenses
General and administrative 3,367,770 2,753,780
Clinical and regulatory 2,695,584 1,471,473
Sales and marketing 755,176 465,347
Impairment of goodwill - 65,945,686
---------------------------------------------------------------------------
6,818,530 70,636,286
---------------------------------------------------------------------------
Loss from operations (6,779,266) (70,557,888)
---------------------------------------------------------------------------
Other income (expense)
Interest income 215,927 410,228
Changes in fair value of warrant obligation 1,500,710 -
Interest and accretion expense (204,896) -
Other (23,785) (6,724)
Minority interest 489,937 -
---------------------------------------------------------------------------
1,977,893 403,504
---------------------------------------------------------------------------
Loss before income taxes (4,801,373) (70,154,384)
Recovery of income taxes 2,222,502 158,792
---------------------------------------------------------------------------
Net loss for the period (2,578,871) (69,995,592)
---------------------------------------------------------------------------
---------------------------------------------------------------------------
Weighted average number of shares outstanding
- basic and diluted 57,304,020 42,186,579
---------------------------------------------------------------------------
---------------------------------------------------------------------------
Net loss per share - basic and diluted (0.05) (1.66)
---------------------------------------------------------------------------
---------------------------------------------------------------------------



OccuLogix, Inc.

CONSOLIDATED BALANCE SHEETS
(expressed in U.S. dollars)
(Unaudited)

June 30, December 31,
2007 2006
--------------------------
$ $
---------------------------------------------------------------------------

ASSETS
Current
Cash and cash equivalents 5,628,916 5,740,697
Short-term investments 9,975,000 9,785,000
Amounts receivable, net 461,400 166,209
Inventory, net 2,784,841 2,715,737
Prepaid expenses 927,004 680,476
Deposit 10,442 10,442
Other current assets 81,000 79,200
---------------------------------------------------------------------------
Total current assets 19,868,603 19,177,761
---------------------------------------------------------------------------
Fixed assets, net 796,380 860,717
Patents and trademarks, net 294,838 234,841
Intangible assets, net 54,763,128 55,683,399
Goodwill 14,446,977 14,446,977
---------------------------------------------------------------------------
Total assets 90,169,926 90,403,695
---------------------------------------------------------------------------
---------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current
Accounts payable 600,215 395,392
Accrued liabilities 2,896,407 2,081,352
Deferred revenue and rent inducement 111,473 9,585
Due to stockholders 156,933 152,406
Obligation under warrants 1,105,766 -
Current portion of other long-term liability 3,000,000 3,000,000
---------------------------------------------------------------------------
Total current liabilities 7,870,794 5,638,735
---------------------------------------------------------------------------
Deferred tax liability, net 9,902,898 18,939,417
Other long-term liability 3,830,400 3,420,609
---------------------------------------------------------------------------
Total liabilities 21,604,092 27,998,761

---------------------------------------------------------------------------
Minority interest 1,138,059 1,184,844
Stockholders' equity
Capital stock
Common stock 57,306 50,627
Par value of $0.001 per share
Authorized: 75,000,000; Issued and
outstanding: June 30, 2007 - 57,306,145;
December 31, 2006 - 50,626,562
Additional paid-in capital 362,772,737 354,320,116
Accumulated deficit (295,402,268) (293,150,653)
---------------------------------------------------------------------------
Total stockholders' equity 67,427,775 61,220,090
---------------------------------------------------------------------------
Total liabilities and stockholders' equity 90,169,926 90,403,695
---------------------------------------------------------------------------
---------------------------------------------------------------------------


Contacts:
OccuLogix, Inc.
Stephen Kilmer
VP, Investor & Public Affairs
(905) 602-0887 ext. 3904
Email: stephen.kilmer@occulogix.com
Website: www.occulogix.com


Source: Market Wire (August 8, 2007 - 7:05 AM EST)

News by QuoteMedia
www.quotem

OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) today announced that it has entered into discussions with JEGC OCC Corp. ("JEGC") for the private placement of approximately $30 million of common stock at a price based upon the average trading price of OccuLogix' common stock at the time of purchase, subject to regulatory approval and to a minimum price of US$1.05 per share.

JEGC is owned by Jefferson EquiCorp Ltd., a private equity firm controlled by David Folk, Managing General Partner of Jefferson Partners, and by Greybrook Corporation, a private equity firm controlled by Elias Vamvakas, Chairman and Chief Executive Officer of OccuLogix.

On May 30, 2007, TLC Vision Corporation (TSX: TLC)(NASDAQ: TLCV) and JEGC announced that JEGC had agreed to purchase TLC Vision's ownership stake in OccuLogix, subject to certain minimum prices and regulatory limitations and further subject to JEGC obtaining satisfactory financing and other customary closing conditions. It is anticipated that if both transactions are completed, JEGC will gain a control position in OccuLogix.

The securities to be offered in this private placement have not been registered under the Securities Act of 1933, as amended (the "Act") or any state securities laws or qualified under any Canadian provincial or territorial securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws or in Canada absent a valid prospectus, or an applicable exemption from the prospectus requirements, under applicable provincial and territorial securities laws.

About Greybrook Corporation

Founded in 1999, Greybrook (www.greybrook.com) is a private equity firm that provides capital to private and public companies, helping them to grow to the next level and maximize their value potential.

About Jefferson Partners

Jefferson Partners (www.jefferson.com) is a technology oriented venture capital firm focused on financing and building innovative world class companies.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. OccuLogix is currently focused in the areas of: Dry AMD through its RHEO(TM) System (www.rheo.com); Glaucoma through its SOLX® 790 Laser and SOLX® Gold Shunt (www.solx.com); and Dry Eye Disease through the company's subsidiary, OcuSense, Inc. (www.ocusense.com).

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.

Contacts:
OccuLogix, Inc.
Stephen Kilmer
VP, Investor & Public Affairs
(905) 602-0887 ext. 3904
Email: stephen.kilmer@occulogix.com
Website: www.occulogix.com

Appears to be goods news if you look at A/H's trading(someone willing to Buy all that stock has to be good news)

TLCV: Enters Agreement to Sell Its Shares of OccuLogix, Inc.
Wednesday, May 30, 2007 16:35Et

TLC Vision Corporation (TLCV) announced that it has entered into an agreement to sell all of its shares of common stock of OccuLogix, Inc. (OCCX) to JEGC OCC Corp. ("JEGC").

JEGC has agreed to purchase 1,904,762 shares of OccuLogix common stock at a price of US$1.05 per share on or before June 22, 2007, subject to customary closing conditions. JEGC will also acquire TLCVision's remaining 18,770,302 shares of OccuLogix common stock, within the next 90 days, at a price based upon average trading price of OccuLogix common stock at the time of purchase, subject to certain minimum prices and regulatory limitations and further subject to JEGC obtaining satisfactory financing and other customary closing conditions.

surf checkout APPA premarket this morning.

surf check out POTP , maybe hit .023

surf, also checkout NVD 1.18, Kinda weird bottom out @1.06- 1.10 last 2 years and gos up to 1.92- 2.00.

Surf, Maybe to 1.38 kinda bounce im thinking.

I just bought some OCCX for a bounce, but this isn't good for this stock....GLTY

Surf, not much vol on the downside and I think next week news may come out for a pop up

OCCX .83 now

OCCX has become too risky at this point. My guess would be that the "going concern" letter from a few weeks ago was the reason for much of the sell off. Too many other small cap bio's that have been clocked over the past month & may be wiser to place some funds in them. On a positive note, OCCX is oversold & can bounce at anytime.

Surf OCCX now 1.01 so I will nibble on some under a buck.

Bought a little OCCX this morning on those lows, most small cap bio's have been B-slapped this past couple of weeks. I plan on going back into many of them, just not sure when that will be. We need a market sell off to correct some of this overall market move. The market saying " sell in May & go away" could be true this year.

surf u check out NVD 1.35 , seem like it gos to 1.06 -1.10 and few months later back up to 1.96.

OCCX has held up very well compared to many other bio's, also I shorted NAV right before it when to the pinks.

NAV ,Navistar stock being delisted 47.75

Say surf I wonder if u can do a test for me on the brokers u have,like put a bid on VSGN 100 shrs and @ .01 on a GTC+extended hours and see what u come up with, like ameriturd say this Security is not eligible for this market and wondering if others brokers do the same. Thanks! also I see STSI went from .75 to over a buck today.

surf, Gee! so many of them u have. Ok your the guy to ask this then, Besides aturd the other three, can a person put in a order lets say VSGN on a gtc+ext and not get the Security is not eligible for this market, because I like to use the seamless trade and aturd won't let me do it but they do allow me to use the ext-am or ext-pm but who wants to keep entering it each day. I like to find a broker that allows me to use a gtc+ext on stocks under a buck this way I set it and forget it kinda thingy. On amex stocks I can use the gtc+ext with no problem under a buck ,its just on the nasdaq stocks I have the problem with aturd when stocks r under a buck. Any input on this matter would be great. Thanks!

surf u might want to keep an eye on AVNR, it had some new on it and went to 3.09 in aftermarket.
After Hours
Last: $ 2.64 After Hours
High: $ 3.09
After Hours
Volume: 152,615 After Hours
Low: $ 2.41

surf if u dont mind what broker r u using. because ameriturd sucks.

I'll be selling some this morning, mainly because we have a gap & no volume.

I have been following and in this one for a while. Nice that we finally got FDA approval. NICE NEWS!!

Some good news out on OCCX today.

http://finance.yahoo.com/q/h?s=OCCX